While CCUS is not recognized as a diagnostic category in WHO 2022, the ICC classification defines it as a distinct diagnostic entity, requiring close clinical follow-up, particularly when high-risk mutations like TP53 are detected [2,47,69]. This evidence concerns the gene TP53 and intrahepatic cholangiocarcinoma.